MENU
+Compare
SBIO
ETF ticker: NYSE ARCA
AS OF
Apr 24, 11:32 AM (EDT)
Price
$28.24
Change
+$0.22 (+0.79%)
Net Assets
79.22M

SBIO stock forecast, quote, news & analysis

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index... Show more

Category: #Health
SBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for SBIO with price predictions
Apr 23, 2025

SBIO's RSI Oscillator climbs out of oversold territory

The RSI Oscillator for SBIO moved out of oversold territory on April 11, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 33 similar instances when the indicator left oversold territory. In of the 33 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 21, 2025. You may want to consider a long position or call options on SBIO as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SBIO just turned positive on April 16, 2025. Looking at past instances where SBIO's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SBIO advanced for three days, in of 320 cases, the price rose further within the following month. The odds of a continued upward trend are .

SBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SBIO entered a downward trend on April 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX).

Industry description

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Market Cap

The average market capitalization across the ALPS Medical Breakthroughs ETF ETF is 1.46B. The market cap for tickers in the group ranges from 60.72M to 5.38B. VRNA holds the highest valuation in this group at 5.38B. The lowest valued company is STRO at 60.72M.

High and low price notable news

The average weekly price growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was 59%. For the same ETF, the average monthly price growth was 68%, and the average quarterly price growth was 86%. STRO experienced the highest price growth at 67%, while YMAB experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was 40%. For the same stocks of the ETF, the average monthly volume growth was 43% and the average quarterly volume growth was 85%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 81
Price Growth Rating: 68
SMR Rating: 84
Profit Risk Rating: 86
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
SBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
ALPS ETFPO Box 328Denver
Phone
855.724.0450
Web
www.alpsfunds.com